SCHEMBL8089430

SCHEMBL8089430

O=C(O)c1ccc2c(-c3ccc(C(O)O)cc3)cccc2c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.53
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
MCL1 Q07820 1/20 0.43
ACMSD Q8TDX5 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TTR P02766 1/20 0.41
PPARG P37231 5/20 0.40
PPARA Q07869 5/20 0.40
PTPRC P08575 2/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8111070 0.87 HDAC8 (0.43) PTPN1HDAC8HDAC6CYP1A2CYP2C9
SCHEMBL10440157 0.84 PTPN1 (0.57) PTPN1HDAC8HDAC6MCL1ACMSD
SCHEMBL31357157 0.81 PTPN1 (0.70) PTPN1CYP1A2CYP2C19TTRPTPRC
SCHEMBL22570620 0.79 P2RY14 (0.54) PTPN1CYP2C9
SCHEMBL30290120 0.79 P2RY14 (0.54) PTPN1CYP2C9
SCHEMBL23796343 0.79 PTPN1 (0.51) PTPN1HDAC8HDAC6MCL1ACMSD
SCHEMBL30290196 0.79 PTPN1 (0.51) PTPN1HDAC8HDAC6MCL1ACMSD
SCHEMBL8105665 0.77 PTPN1 (0.64) PTPN1CYP1A2CYP2C19TTRPTPRC
SCHEMBL9303054 0.75 P2RY14 (0.55) TTR
SCHEMBL5788498 0.75 HDAC8 (0.68) HDAC8HDAC6MCL1ACMSDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2000515506-A 2000-11-21 JP claimed
EP-0920312-A4 APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS GALDERMA RES & DEV (FR) 2000-11-02 EP claimed
EP-0920312-A1 APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS Galderma Research & Development (FR) 1999-06-09 EP claimed
WO-1998001132-A1 APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-01-15 WO claimed
EP-0920312-A4 APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS GALDERMA RES & DEV (FR) 2000-11-02 EP disclosed
EP-0920312-A1 APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS Galderma Research & Development (FR) 1999-06-09 EP disclosed
WO-1998001132-A1 APOPTOSIS INDUCING ADAMANTYL DERIVATIVES AND THEIR USAGE AS ANTI-CANCER AGENTS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 1998-01-15 WO disclosed